JP2024515289A5 - - Google Patents
Info
- Publication number
- JP2024515289A5 JP2024515289A5 JP2023562834A JP2023562834A JP2024515289A5 JP 2024515289 A5 JP2024515289 A5 JP 2024515289A5 JP 2023562834 A JP2023562834 A JP 2023562834A JP 2023562834 A JP2023562834 A JP 2023562834A JP 2024515289 A5 JP2024515289 A5 JP 2024515289A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- use according
- tubb4a
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175988P | 2021-04-16 | 2021-04-16 | |
| US63/175,988 | 2021-04-16 | ||
| PCT/US2022/025246 WO2022221777A1 (en) | 2021-04-16 | 2022-04-18 | Compositions and methods useful for the treatment of h-abc leukodystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515289A JP2024515289A (ja) | 2024-04-08 |
| JP2024515289A5 true JP2024515289A5 (enExample) | 2025-04-25 |
Family
ID=83639782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562834A Pending JP2024515289A (ja) | 2021-04-16 | 2022-04-18 | Ｈ－ａｂｃ白質ジストロフィーの治療に有用な組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240200065A1 (enExample) |
| EP (1) | EP4323063A4 (enExample) |
| JP (1) | JP2024515289A (enExample) |
| CN (1) | CN117561067A (enExample) |
| AU (1) | AU2022257101A1 (enExample) |
| CA (1) | CA3215478A1 (enExample) |
| WO (1) | WO2022221777A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025030064A1 (en) * | 2023-08-01 | 2025-02-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing tubb4a expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2020227713A1 (en) * | 2019-05-09 | 2020-11-12 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same |
-
2022
- 2022-04-18 US US18/287,150 patent/US20240200065A1/en active Pending
- 2022-04-18 WO PCT/US2022/025246 patent/WO2022221777A1/en not_active Ceased
- 2022-04-18 CN CN202280043000.2A patent/CN117561067A/zh active Pending
- 2022-04-18 AU AU2022257101A patent/AU2022257101A1/en active Pending
- 2022-04-18 CA CA3215478A patent/CA3215478A1/en active Pending
- 2022-04-18 JP JP2023562834A patent/JP2024515289A/ja active Pending
- 2022-04-18 EP EP22789092.8A patent/EP4323063A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019226001B2 (en) | CAMK2D antisense oligonucleotides and uses thereof | |
| JP2023103244A5 (enExample) | ||
| ES2886147T3 (es) | MiARN para el tratamiento del cáncer de cabeza y de cuello | |
| US6537973B1 (en) | Oligonucleotide inhibition of protein kinase C | |
| US20200291406A1 (en) | Preventive or therapeutic agent for fibrosis | |
| WO2017135397A1 (ja) | 補体ｂ因子の発現を抑制するアンチセンスオリゴヌクレオチド | |
| CN106467915A (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 | |
| JP2024515289A5 (enExample) | ||
| JP2023506842A5 (enExample) | ||
| CN102028947B (zh) | Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途 | |
| WO2025026228A1 (zh) | Cfb抑制剂组合物及其应用 | |
| US20240376473A1 (en) | Antisense compound for modulating wfdc2 expression | |
| JP2024028895A (ja) | オリゴヌクレオチド分子及び腫瘍治療におけるその応用 | |
| WO2026061399A1 (en) | Rnai agent for inhibiting expression of xanthine dehydrogenase (xdh) and methods of use thereof | |
| EP4403634A1 (en) | Antisense compound that regulates expression of wfdc2 | |
| CN115141848A (zh) | 一种用于治疗亨廷顿病的rna递送系统 | |
| WO2026085164A2 (en) | Snca irna formulations and methods of use thereof | |
| TW202546228A (zh) | 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑 | |
| TW202613311A (zh) | 靶向pnpla3的雙鏈核糖核酸 | |
| US20260098265A1 (en) | Compositions and methods for treatment of spinocerebellar ataxias | |
| TW202609056A (zh) | 靶向sod1的寡核苷酸 | |
| CN118974255A (zh) | 用于治疗癫痫的组合物和方法 | |
| WO2025256564A1 (en) | iRNA COMPOSITION AND METHOD OF USING SAME | |
| CN119968465A (zh) | 一种siRNA、siRNA缀合物、药物组合物及其用途 | |
| WO2026035968A1 (en) | In vivo nickase-based editing of the angiotensinogen gene |